MedTrace Logo

Imaging of CB1 Receptors Using (11C)SD5024

NCT01399398 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-11-29

No results posted yet for this study

Summary

Background:

\- The cannabinoid type 1 (CB1) receptor is a protein found on some brain cells. It may play a role in obesity or some psychiatric disorders such as schizophrenia. Imaging studies like positron emission tomography (PET) can show where CB1 receptors are located. A new radioactive chemical, 11C-SD5024, may be able to show these receptors more clearly than previous radioactive chemicals. Better images of CB1 receptors in the brain may help improve our understanding of obesity and psychiatric disorders. This information may lead to better treatments.

Objectives:

\- To test how well a new radioactive chemical, 11C-SD5024, is taken up by the brain during imaging studies.

Eligibility:

\- Healthy volunteers between 18 and 50 years of age who are able to have positron emission tomography scans.

Design:

* All participants will be screened with a physical exam, medical history, and blood tests.
* Participants will be in one of three groups for the study. Each group will receive 11C-SD5024 and have a different set of imaging studies.
* Group 1 will have a magnetic resonance imaging (MRI) scan and PET scan of the brain. They will also have blood and urine tests.
* Group 2 will have a whole-body PET scan, as well as blood and urine tests.
* Group 3 will have an MRI scan of the brain, followed by two PET scans of the brain. They will also have blood and urine tests. The two PET scans can happen on the same day or on two different days.

Conditions

  • Healthy

Interventions

PROCEDURE

Brain Scan-PET

PROCEDURE

Brain Scan-MRI

PROCEDURE

Arterial Line

PROCEDURE

Venous Line

PROCEDURE

Blood Sampling

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Masahiro Fujita, M.D. · National Institute of Mental Health (NIMH)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-22
Primary Completion
2013-12-18
Completion
2013-12-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399398 on ClinicalTrials.gov